Probiotics for pediatric functional abdominal pain: which strains have evidence

Recurrent functional abdominal pain affects an estimated 10–15% of school-age children in Western countries. The Rome IV criteria categorize most cases as functional abdominal pain (FAP), irritable bowel syndrome (IBS), or functional dyspepsia. The pathophysiology is multi-factorial — visceral hypersensitivity, altered gut motility, microbiota differences, and central nervous system processing all contribute. Probiotics are a plausible adjunct, and a substantial body of pediatric trials has accumulated. The picture that emerges is strain-specific: a few products work modestly, most do not.

The strongest strain: Lactobacillus rhamnosus GG

LGG has the largest randomized evidence base in pediatric FAP and IBS. A 2010 RCT in 141 children with abdominal pain randomized them to LGG (3×10⁹ CFU twice daily) or placebo for 8 weeks. The treatment group showed reduced pain frequency (40% versus 25% with at least 50% reduction) and intensity, with significantly more pain-free children at 8 weeks [1]. Two subsequent meta-analyses pooling LGG trials reported moderate-quality evidence for symptom improvement, particularly in the IBS subgroup of pediatric functional abdominal pain disorders [2].

Lactobacillus reuteri DSM 17938

L. reuteri DSM 17938 — better known for its evidence in infant colic — has also been tested in older children with FAP. A 2014 trial randomized 60 children aged 6–16 with FAP to L. reuteri DSM 17938 (10⁸ CFU/day) or placebo for 4 weeks. The treatment group showed reduced pain intensity and frequency at 4 weeks, with the effect sustained at 8-week follow-up. A 2019 trial reproduced the finding in a slightly different population. The total evidence base is smaller than LGG but trends positive [3].

VSL#3 (now Visbiome) — multi-strain

The high-dose multi-strain formulation containing 8 species (4 Lactobacillus, 3 Bifidobacterium, and Streptococcus thermophilus) has been tested in pediatric IBS. A 2010 trial in 59 children with Rome III IBS showed significant improvement in abdominal pain and family quality of life with VSL#3 versus placebo over 6 weeks. The product is well-characterized and the effect size is comparable to LGG, though the dose required (typically 1 sachet per day, delivering 450 billion CFU) is substantially higher than single-strain products [4].

Strains without convincing pediatric evidence

Saccharomyces boulardii has good evidence for antibiotic-associated diarrhea but mixed or null results in pediatric FAP. Bifidobacterium infantis 35624 (the IBS strain) has not been studied in pediatric populations to the same depth as in adults. Most generic multi-strain "kids' probiotic" gummies sold over the counter contain doses and strain combinations that have not been tested in any pediatric FAP trial. Marketing language equating "billion CFU" counts to clinical effect is not supported by strain-specific data [5].

Mechanisms that may matter

Pediatric FAP appears to involve increased intestinal permeability, low-grade mucosal inflammation, and altered serotonergic signaling. Probiotic strains that strengthen tight junctions, modulate TLR signaling, or alter visceral pain pathways through gut-brain axis effects have biologic plausibility. LGG, in particular, has well-documented epithelial barrier effects in cell culture and animal models that align with the proposed mechanisms in FAP [6].

Practical use in children

For a child meeting Rome IV criteria for FAP or IBS with at least 4 weeks of weekly symptoms interfering with daily activities, a 4–8 week trial of LGG 10⁹–10¹⁰ CFU/day or L. reuteri DSM 17938 at standard pediatric dose is a defensible adjunct after pediatric or pediatric gastroenterology evaluation rules out organic disease. Continued use beyond 12 weeks should be re-evaluated for benefit. The product chosen should specify the strain by full nomenclature (genus, species, and strain identifier), not just the species, because effects do not generalize across strains within a species [7].

Safety

Probiotic supplementation is generally safe in immunocompetent children, with mild and self-limiting GI side effects in a small fraction of users. Caution is needed in immunocompromised children, those with central venous catheters, and those with severe acute pancreatitis — small numbers of probiotic bacteremia case reports exist in these populations. Children with short-bowel syndrome should not start probiotics without specialist input.

The bottom line

For school-age children with functional abdominal pain or pediatric IBS, the evidence supports a strain-specific trial of LGG (Lactobacillus rhamnosus GG) or L. reuteri DSM 17938 for 4–8 weeks, with measurable improvement in pain frequency and intensity expected in a subset. Multi-strain products like Visbiome have similar effect sizes at higher cost. Generic over-the-counter children's probiotics with undocumented strain composition do not have evidence. Probiotics are an adjunct to age-appropriate behavioral and dietary management, not a substitute for clinician evaluation of recurrent pain.